•Ulcerative colitis: from molecular pathophysiology to management and the emerging role of natural and pharmacological drug candidates
•Discovery of novel ibuprofen-1,3,4-thiadiazole derivatives attenuating ulcerative colitis by regulating MAPK-mediated inflammation and restoring intestinal immune homeostasis
•Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry
•Real-world outcomes of tumour necrosis factor inhibitor (TNFi) cyclers versus mechanism-of-action switchers among ulcerative colitis patients who failed first-line TNFi
•Proximally dominant inflammation at colonoscopy predicts pan-colonic histological remission following oral vancomycin therapy in pediatric ulcerative colitis